Showing 1672 results
-
Story /Combination of two compounds shows promise in the lab
-
Story /Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Story /Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery
-
Press release /Der Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
-
Webform /Novartis is committed to improving the accessibility and usability of our websites, ensuring that content and services are available to all visitors, regardless of their ability or the technology…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1…
-
Press release /In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (…
-
Press release /33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent,…
-
Press release /After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor…